SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab treatment for hepatocellular carcinoma.
Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Clinical characteristics, management and outcomes in immune checkpoint inhibitor-induced central nervous system demyelinating disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo present a case of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab therapy and systematically review the literature on immune checkpoint inhibitor (ICI)-associated antibody-mediated central nervous system (CNS) inflammatory demyelinating diseases.
backgroundWhile ICIs have transformed cancer treatment, they can trigger diverse neurological immune-related adverse events. Autoimmune demyelinating disorders remain uncommon, with sparse published cases linking ICIs to MOGAD. We report a novel case of MOGAD developing after administration of atezolizumab plus bevacizumab.
methodWe conducted a retrospective chart review of the index case and performed a systematic literature review (January 1, 2001, to April 30, 2025) of reported antibody-mediated CNS demyelinating disorders associated with ICIs.
resultThis represents the first documented MOGAD case during atezolizumab and bevacizumab treatment for hepatocellular carcinoma. The patient achieved a favorable response to intravenous methylprednisolone and immunoglobulin therapy. Further research is warranted to elucidate the pathogenesis underlying ICI-associated MOGAD.
Indexed as
Identifiers
41405648What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.